Hepatic decompensating events in patients with type 2 diabetes
(Comparison between propensity−score matched cohorts)

Cohort size	Exposure cohort	Comparison cohort	# of cases (overall risk) (Exposure cohort)	# of cases (overall risk) (Comparison cohort)		HR (95% CI)
		Overall				
46,470	GLP−1RA(+)Insulin(−)	Insulin(+)GLP−1RA(−)	302 (0.65%)	1,670 (3.59%)		0.17 (0.15−0.19)
46,260	GLP−1RA(+)Metformin(−)	Metformin(+)GLP−1RA(−)	1,360 (2.94%)	1,527 (3.30%)		0.91 (0.84−0.98)
102,868	GLP−1RA(+)DDP−4(−)	DPP−4(+)GLP−1RA(−)	2,402 (2.34%)	3,262 (3.17%)		0.68 (0.65−0.72)
53,204	GLP−1RA(+)SGLT2(−)	SGLT2(+)GLP−1RA(−)	1,351 (2.54%)	1,462 (2.75%)		0.88 (0.82−0.95)
93,354	GLP−1RA(+)SU(−)	SU(+)GLP−1RA(−)	2,238 (2.40%)	3,013 (3.23%)		0.70 (0.66−0.74)
62,618	GLP−1RA(+)TZD(−)	TZD(+)GLP−1RA(−)	1,376 (2.20%)	1,594 (2.55%)		0.82 (0.76−0.88)
		No insulin				
13,344	GLP−1RA(+)Metformin(−)	Metformin(+)GLP−1RA(−)	99 (0.74%)	127 (0.95%)		0.84 (0.64−1.09)
32,187	GLP−1RA(+)DDP−4(−)	DPP−4(+)GLP−1RA(−)	198 (0.62%)	283 (0.88%)		0.66 (0.55−0.79)
21,155	GLP−1RA(+)SGLT2(−)	SGLT2(+)GLP−1RA(−)	158 (0.75%)	164 (0.78%)		0.94 (0.75−1.17)
28,461	GLP−1RA(+)SU(−)	SU(+)GLP−1RA(−)	179 (0.63%)	308 (1.08%)		0.56 (0.46−0.67)
22,182	GLP−1RA(+)TZD(−)	TZD(+)GLP−1RA(−)	134 (0.60%)	180 (0.81%)		0.71 (0.57−0.89)

0.20 0.30   0.50 0.70 1.0   2.0 3.00 4.0

Hazard Ratio (HR)